SenzaGen Gains First Patent for GARDpotency

June 14, 2019
Pharmaceutical Technology Editors

SenzaGen has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.

Swedish-based company, SenzaGen, has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.

“Getting this patent approved for the European market is commercially interesting, as there is a ban within the European Union on the sale of animal-tested cosmetic products,” said Anki Malmborg Hager, CEO of SenzaGen, in a June 13, 2019 press statement. “Furthermore, to quantify how strong the allergenic effect is according to classification and labeling (CLP/GHS) is a requirement in the EU chemical regulation REACH [Registration, Evaluation, Authorization, and Restriction of Chemicals]. As the only company in the world, SenzaGen can now offer an animal-free test method for this.”

The company’s GARD portfolio of products comprises a set of allergy tests that are performed on human cells in-vitroin combination with artificial intelligence, which can be used to replace animal testing in various industries, including pharma. There are several other ongoing patent applications for GARDpotency and other products in the portfolio.

Source: SenzaGen